// App-Quantinova.ai

2046 : PC or PCV? That is the question: A retrospective review of primary anaplastic oligodendroglial tumors treated with procarbazine and CCNU without or with vincristine.

Researchers

Presenter

  • Courtney C. Webre

Principal Investigators

  • Nicole A. Shonka

  • John Frederick De Groot

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Nebraska Medical Center, Omaha, NETexas A&M Health Science Center, Bryan, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Anaplastic oligodendroglial tumors

  • Brain cancer

  • Solid malignancies

Biomarkers

  • Hematocrit

Drug/Treatment

  • procarbazine

  • Vincristine

  • Lomustine

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved